Lupin Launches Generic Drug Used For Prevention Of Organ Rejection In Kidney Transplant In US

Lupin Launches Generic Drug Used For Prevention Of Organ Rejection In Kidney Transplant In US

By, Admin 9 April 2020

Drug firm Lupin on Monday said it has launched generic Mycophenolic acid delayed-release tablets, which is used to prevent organ rejection in patients receiving kidney transplants in the US market. The company has launched the tablets in the strengths of 180 mg and 360 mg, Lupin said in a statement.Company's alliance partner Concord Biotech Ltd had received an approval from the United States Food and Drug Administration (USFDA) earlier for the product, it added.The tablets are generic version of Novartis Pharmaceuticals Corporation's Myfortic delayed-release tablets, 180 mg and 360 mg, Lupin said.According to IQVIA MAT February 2020 data, Mycophenolic acid delayed-release tablets USP had an annual sales of around USD 156 million in the US, it added.The tablets are indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant., Lupin said. It is indicated for use in combination with cyclosporine and corticosteroids, it added.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!